The Experts below are selected from a list of 16635 Experts worldwide ranked by ideXlab platform
Brian I Rini - One of the best experts on this subject based on the ideXlab platform.
-
Thyroid Function Test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
Annals of Oncology, 2008Co-Authors: Ila Tamaskar, Adriana G Ioachimescu, Jorge A Garcia, Paul Elson, Laura S Wood, Tarek Mekhail, Robert Dreicer, Robert Bukowski, Brian I RiniAbstract:Background: Sorafenib is an orally bioavailable vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity in metastatic renal cell carcinoma (RCC). Sunitinib, also a VEGFR inhibitor, induces biochemical hypoThyroidism in 85% of metastatic RCC patients, the majority of whom have signs or symptoms of hypoThyroidism. Hence, the incidence of Thyroid Function Test (TFT) abnormalities in patients with metastatic RCC receiving sorafenib was investigated. Patients and methods: Sixty-eight patients with metastatic RCC were treated with sorafenib at the Cleveland Clinic Taussig Cancer Center, and 39 patients had TFTs available. Results: Eight patients (21%) had Thyroid dysFunction possibly caused by sorafenib [seven hypoThyroidism (18%) and one hyperThyroidism (3%)] and eight additional patients (21%) had findings compatible with nonThyroidal illness. Only two patients had clinical signs and symptoms secondary to Thyroid dysFunction and received Thyroid hormone replacement. Conclusions: In summary, clinically significant TFT abnormalities were not common in patients treated with sorafenib, and replacement therapy was rarely indicated. TFTs should be measured before sorafenib therapy in RCC patients and subsequently only if clinically indicated.
-
hypoThyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Journal of the National Cancer Institute, 2007Co-Authors: Brian I Rini, Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Phillip Shaheen, Renee Salas, Sethu Reddy, Ronald M BukowskiAbstract:Sunitinib is an inhibitor of the vascular endothelial growth factor and platelet-derived growth factor receptors, and it has antitumor activity in metastatic renal cell carcinoma and gastroinTestinal stromal tumors. To further investigate the fatigue associated with sunitinib therapy, Thyroid Function Tests were performed on patients with metastatic renal cell carcinoma who were receiving sunitinib. Seventy-three patients with metastatic renal cell carcinoma were treated with sunitinib at the Cleveland Clinic Taussig Cancer Center, and 66 of them had Thyroid Function Test results available. Fifty-six (85%) of the 66 patients had one or more abnormality in their Thyroid Function Test results, consistent with hypoThyroidism, and 47 (84%) of the 56 patients with abnormal Thyroid Function Tests had signs and/or symptoms possibly related to hypoThyroidism. Thyroid hormone replacement was undertaken in 17 patients, and symptoms improved in nine of them. Thyroid Function Test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted.
-
Thyroid Function Test tft abnormalities in patients pts with metastatic renal cell carcinoma rcc treated with sorafenib
Journal of Clinical Oncology, 2006Co-Authors: Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Ronald M Bukowski, Jaya Unnithan, A Iochimescu, Brian I RiniAbstract:4605 Background: Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors. It has anti-tumor activity in m...
Ila Tamaskar - One of the best experts on this subject based on the ideXlab platform.
-
Thyroid Function Test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
Annals of Oncology, 2008Co-Authors: Ila Tamaskar, Adriana G Ioachimescu, Jorge A Garcia, Paul Elson, Laura S Wood, Tarek Mekhail, Robert Dreicer, Robert Bukowski, Brian I RiniAbstract:Background: Sorafenib is an orally bioavailable vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity in metastatic renal cell carcinoma (RCC). Sunitinib, also a VEGFR inhibitor, induces biochemical hypoThyroidism in 85% of metastatic RCC patients, the majority of whom have signs or symptoms of hypoThyroidism. Hence, the incidence of Thyroid Function Test (TFT) abnormalities in patients with metastatic RCC receiving sorafenib was investigated. Patients and methods: Sixty-eight patients with metastatic RCC were treated with sorafenib at the Cleveland Clinic Taussig Cancer Center, and 39 patients had TFTs available. Results: Eight patients (21%) had Thyroid dysFunction possibly caused by sorafenib [seven hypoThyroidism (18%) and one hyperThyroidism (3%)] and eight additional patients (21%) had findings compatible with nonThyroidal illness. Only two patients had clinical signs and symptoms secondary to Thyroid dysFunction and received Thyroid hormone replacement. Conclusions: In summary, clinically significant TFT abnormalities were not common in patients treated with sorafenib, and replacement therapy was rarely indicated. TFTs should be measured before sorafenib therapy in RCC patients and subsequently only if clinically indicated.
-
hypoThyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Journal of the National Cancer Institute, 2007Co-Authors: Brian I Rini, Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Phillip Shaheen, Renee Salas, Sethu Reddy, Ronald M BukowskiAbstract:Sunitinib is an inhibitor of the vascular endothelial growth factor and platelet-derived growth factor receptors, and it has antitumor activity in metastatic renal cell carcinoma and gastroinTestinal stromal tumors. To further investigate the fatigue associated with sunitinib therapy, Thyroid Function Tests were performed on patients with metastatic renal cell carcinoma who were receiving sunitinib. Seventy-three patients with metastatic renal cell carcinoma were treated with sunitinib at the Cleveland Clinic Taussig Cancer Center, and 66 of them had Thyroid Function Test results available. Fifty-six (85%) of the 66 patients had one or more abnormality in their Thyroid Function Test results, consistent with hypoThyroidism, and 47 (84%) of the 56 patients with abnormal Thyroid Function Tests had signs and/or symptoms possibly related to hypoThyroidism. Thyroid hormone replacement was undertaken in 17 patients, and symptoms improved in nine of them. Thyroid Function Test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted.
-
Thyroid Function Test tft abnormalities in patients pts with metastatic renal cell carcinoma rcc treated with sorafenib
Journal of Clinical Oncology, 2006Co-Authors: Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Ronald M Bukowski, Jaya Unnithan, A Iochimescu, Brian I RiniAbstract:4605 Background: Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors. It has anti-tumor activity in m...
Ronald M Bukowski - One of the best experts on this subject based on the ideXlab platform.
-
hypoThyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Journal of the National Cancer Institute, 2007Co-Authors: Brian I Rini, Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Phillip Shaheen, Renee Salas, Sethu Reddy, Ronald M BukowskiAbstract:Sunitinib is an inhibitor of the vascular endothelial growth factor and platelet-derived growth factor receptors, and it has antitumor activity in metastatic renal cell carcinoma and gastroinTestinal stromal tumors. To further investigate the fatigue associated with sunitinib therapy, Thyroid Function Tests were performed on patients with metastatic renal cell carcinoma who were receiving sunitinib. Seventy-three patients with metastatic renal cell carcinoma were treated with sunitinib at the Cleveland Clinic Taussig Cancer Center, and 66 of them had Thyroid Function Test results available. Fifty-six (85%) of the 66 patients had one or more abnormality in their Thyroid Function Test results, consistent with hypoThyroidism, and 47 (84%) of the 56 patients with abnormal Thyroid Function Tests had signs and/or symptoms possibly related to hypoThyroidism. Thyroid hormone replacement was undertaken in 17 patients, and symptoms improved in nine of them. Thyroid Function Test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted.
-
Thyroid Function Test tft abnormalities in patients pts with metastatic renal cell carcinoma rcc treated with sorafenib
Journal of Clinical Oncology, 2006Co-Authors: Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Ronald M Bukowski, Jaya Unnithan, A Iochimescu, Brian I RiniAbstract:4605 Background: Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors. It has anti-tumor activity in m...
Robert Dreicer - One of the best experts on this subject based on the ideXlab platform.
-
Thyroid Function Test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
Annals of Oncology, 2008Co-Authors: Ila Tamaskar, Adriana G Ioachimescu, Jorge A Garcia, Paul Elson, Laura S Wood, Tarek Mekhail, Robert Dreicer, Robert Bukowski, Brian I RiniAbstract:Background: Sorafenib is an orally bioavailable vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity in metastatic renal cell carcinoma (RCC). Sunitinib, also a VEGFR inhibitor, induces biochemical hypoThyroidism in 85% of metastatic RCC patients, the majority of whom have signs or symptoms of hypoThyroidism. Hence, the incidence of Thyroid Function Test (TFT) abnormalities in patients with metastatic RCC receiving sorafenib was investigated. Patients and methods: Sixty-eight patients with metastatic RCC were treated with sorafenib at the Cleveland Clinic Taussig Cancer Center, and 39 patients had TFTs available. Results: Eight patients (21%) had Thyroid dysFunction possibly caused by sorafenib [seven hypoThyroidism (18%) and one hyperThyroidism (3%)] and eight additional patients (21%) had findings compatible with nonThyroidal illness. Only two patients had clinical signs and symptoms secondary to Thyroid dysFunction and received Thyroid hormone replacement. Conclusions: In summary, clinically significant TFT abnormalities were not common in patients treated with sorafenib, and replacement therapy was rarely indicated. TFTs should be measured before sorafenib therapy in RCC patients and subsequently only if clinically indicated.
-
hypoThyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Journal of the National Cancer Institute, 2007Co-Authors: Brian I Rini, Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Phillip Shaheen, Renee Salas, Sethu Reddy, Ronald M BukowskiAbstract:Sunitinib is an inhibitor of the vascular endothelial growth factor and platelet-derived growth factor receptors, and it has antitumor activity in metastatic renal cell carcinoma and gastroinTestinal stromal tumors. To further investigate the fatigue associated with sunitinib therapy, Thyroid Function Tests were performed on patients with metastatic renal cell carcinoma who were receiving sunitinib. Seventy-three patients with metastatic renal cell carcinoma were treated with sunitinib at the Cleveland Clinic Taussig Cancer Center, and 66 of them had Thyroid Function Test results available. Fifty-six (85%) of the 66 patients had one or more abnormality in their Thyroid Function Test results, consistent with hypoThyroidism, and 47 (84%) of the 56 patients with abnormal Thyroid Function Tests had signs and/or symptoms possibly related to hypoThyroidism. Thyroid hormone replacement was undertaken in 17 patients, and symptoms improved in nine of them. Thyroid Function Test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted.
-
Thyroid Function Test tft abnormalities in patients pts with metastatic renal cell carcinoma rcc treated with sorafenib
Journal of Clinical Oncology, 2006Co-Authors: Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Ronald M Bukowski, Jaya Unnithan, A Iochimescu, Brian I RiniAbstract:4605 Background: Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors. It has anti-tumor activity in m...
Laura S Wood - One of the best experts on this subject based on the ideXlab platform.
-
Thyroid Function Test abnormalities in patients with metastatic renal cell carcinoma treated with sorafenib
Annals of Oncology, 2008Co-Authors: Ila Tamaskar, Adriana G Ioachimescu, Jorge A Garcia, Paul Elson, Laura S Wood, Tarek Mekhail, Robert Dreicer, Robert Bukowski, Brian I RiniAbstract:Background: Sorafenib is an orally bioavailable vascular endothelial growth factor receptor (VEGFR) inhibitor with antitumor activity in metastatic renal cell carcinoma (RCC). Sunitinib, also a VEGFR inhibitor, induces biochemical hypoThyroidism in 85% of metastatic RCC patients, the majority of whom have signs or symptoms of hypoThyroidism. Hence, the incidence of Thyroid Function Test (TFT) abnormalities in patients with metastatic RCC receiving sorafenib was investigated. Patients and methods: Sixty-eight patients with metastatic RCC were treated with sorafenib at the Cleveland Clinic Taussig Cancer Center, and 39 patients had TFTs available. Results: Eight patients (21%) had Thyroid dysFunction possibly caused by sorafenib [seven hypoThyroidism (18%) and one hyperThyroidism (3%)] and eight additional patients (21%) had findings compatible with nonThyroidal illness. Only two patients had clinical signs and symptoms secondary to Thyroid dysFunction and received Thyroid hormone replacement. Conclusions: In summary, clinically significant TFT abnormalities were not common in patients treated with sorafenib, and replacement therapy was rarely indicated. TFTs should be measured before sorafenib therapy in RCC patients and subsequently only if clinically indicated.
-
hypoThyroidism in patients with metastatic renal cell carcinoma treated with sunitinib
Journal of the National Cancer Institute, 2007Co-Authors: Brian I Rini, Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Phillip Shaheen, Renee Salas, Sethu Reddy, Ronald M BukowskiAbstract:Sunitinib is an inhibitor of the vascular endothelial growth factor and platelet-derived growth factor receptors, and it has antitumor activity in metastatic renal cell carcinoma and gastroinTestinal stromal tumors. To further investigate the fatigue associated with sunitinib therapy, Thyroid Function Tests were performed on patients with metastatic renal cell carcinoma who were receiving sunitinib. Seventy-three patients with metastatic renal cell carcinoma were treated with sunitinib at the Cleveland Clinic Taussig Cancer Center, and 66 of them had Thyroid Function Test results available. Fifty-six (85%) of the 66 patients had one or more abnormality in their Thyroid Function Test results, consistent with hypoThyroidism, and 47 (84%) of the 56 patients with abnormal Thyroid Function Tests had signs and/or symptoms possibly related to hypoThyroidism. Thyroid hormone replacement was undertaken in 17 patients, and symptoms improved in nine of them. Thyroid Function Test abnormalities appear to be common in patients with metastatic renal cell carcinoma treated with sunitinib, and routine monitoring is warranted.
-
Thyroid Function Test tft abnormalities in patients pts with metastatic renal cell carcinoma rcc treated with sorafenib
Journal of Clinical Oncology, 2006Co-Authors: Ila Tamaskar, Jorge A Garcia, Laura S Wood, Robert Dreicer, Ronald M Bukowski, Jaya Unnithan, A Iochimescu, Brian I RiniAbstract:4605 Background: Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor of vascular endothelial growth factor and platelet-derived growth factor receptors. It has anti-tumor activity in m...